ArticleEuropean child & adolescent psychiatry2026
Hallucinations associated with bilastine in a teenager: case report and disproportionality analysis in VigiBase
Article in European child & adolescent psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bilastine is a second-generation H1-antihistamine considered to have minimal central nervous system penetration and low anticholinergic activity. Neuropsychiatric adverse drug reactions (ADRs), including hallucinations, are not expected with bilastine, although such reactions have been reported with other second-generation antihistamines (sgAH). We report the case of a 13-year-old girl who developed visual hallucinations and panic attacks shortly after starting treatment with bilastine, after having experienced a recurrent sensation of presence while taking desloratadine. The patient's symptoms resolved progressively after discontinuation of bilastine, with a Naranjo score of 6 indicating probable causality. VigiBase
Indexed as
Identifiers
42848058What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.